P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure

Abstract

6.6ng/ml respectively at 15 days post-LT. 20 (16%) on basiliximab had ACR vs 72/188 (38%) controls (p = 0.001). Of those not on basiliximab, 35% (35/97) with TAC levels >5ng/ml vs 41% (38/92) with TAC 50 years (p 5ng/ml at week 1 post-LT (p = 0.003, OR=0.4, 95%CI 0.3–0.7) and mean CNI levels >7ng/ml up to 15 days postLT (p = 0.019, OR=0.85, 95%CI 0.75–0.97). The same factors were associated with mild renal impairment (eGFR 7ng/ml at day 15 post-LT (p = 0.003, OR=1.9, 95%CI 1.2–2.9) and use of steroids >3 months post-LT (p = 0.006, OR=0.7, 95%CI 0.5–0.9). Conclusions: Basiliximab use allows reduced TAC trough levels with less episodes of ACR compared with the control group. However, TAC trough levels <7ng/ml at 15 days post-LT regardless of basiliximab use, were protective of renal function without predisposing to ACR in patients with renal impairment at baseline.